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We respectfully acknowledge that the work to complete this rapid guidance document was hosted 
on Treaty 6 territory, a traditional gathering place for diverse Indigenous peoples including the Cree, 
Blackfoot, Métis, Nakota Sioux, Iroquois, Dene, Ojibway/Saulteaux/Anishinaabe, Inuit, and many 
others.
About the Canadian Research Initiative in Substance Misuse 
Funded by the Canadian Institutes of Health Research (CIHR), the Canadian Research Initiative in 
Substance Misuse (CRISM) is a national research-practice-policy network focused on substance 
use disorders, comprising four large interdisciplinary regional teams (Nodes) representing British 
Columbia, the Prairie Provinces, Ontario, and Quebec/Atlantic. Each CRISM node includes regional 
research scientists, service providers, policy makers, community leaders, and people with lived 
experience of substance use disorders. CRISM’s mission is to translate the best scientific evidence 
into clinical practice, health services, and policy change. More information about CRISM can be found 
at: https://crism.ca.
About this Document
This document is one of a series of six national guidance documents, rapidly developed by the CRISM 
network at the request of the Government of Canada. Collectively, the six documents address urgent 
needs of people who use drugs, service providers, and decision makers in relation to the COVID-19 
pandemic. The urgent nature of this work required rapid development and dissemination of this 
guidance. This, and the continuing evolution of the knowledge base regarding COVID-19, precluded 
CRISM from conducting a comprehensive review of the relevant literature. However, when available, 
scientific evidence is cited in support of the expert advice offered herein.
The guidance provided in this document is subject to change as new information becomes available. 
Readers should note that the intent of this document is to provide general guidance rather than 
detailed procedural and logistical advice. Readers are advised to consult local Public Health and medical 
authorities for specific input on navigating their own unique regulatory and policy environments, as 
necessary.
The CRISM/COVID-19 guidance documents cover the following topics:
• Supporting People Who Use Substances in Shelter Settings During the COVID-19 Pandemic
• Telemedicine Support for Addiction Services
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• Harm Reduction Worker Safety
• Recovery Environments
• Supporting People Who Use Substance in Acute Care Settings (this document)
• Strategies to Help Individuals Self-Isolate for People who use Drugs
Completed documents may be accessed at: https://crism.ca/projects/covid/. Each document was 
developed by a core CRISM authorship committee, drawing on expert knowledge, available scientific 
evidence, and a review of relevant documentation from Public Health authorities. Draft documents 
produced by each authorship committee were reviewed by pan-Canadian panels of content and 
clinical experts. People with lived and living experience of substance use have participated in the 
production of the CRISM/COVID-19 guidance document series, either as part of review or authorship 
committees.  A Canadian Institutes of Health Research (CIHR) Directed Operating Grant to CRISM 
provided funding for this work.
Disclaimer for Health Care Providers 
The recommendations in this guidance document represent the view of the National Operational 
Guidance Document Review Committee, arrived at after careful consideration of the available 
scientific evidence and external expert peer review. The application of the guidance contained in 
this document does not override the responsibility of health care professionals to make decisions 
appropriate to the needs, preferences, and values of an individual patient, in consultation with that 
patient (and their guardian[s] or family members, when appropriate), and, when appropriate, external 
experts (e.g., specialty consultation). When exercising clinical judgment in caring for patients, health 
care professionals may take this guidance document into account while upholding their duties to 
adhere to the fundamental principles and values of their relevant codes of ethics. Nothing in this 
guidance document should be interpreted in a way that would be inconsistent with compliance with 
those duties.
Legal Disclaimer 
While the individuals and groups involved in the production of this document have made every effort 
to ensure the accuracy of the information contained in this guidance document, please note that 
the information is provided “as is” and that CIHR and CRISM make no representation or warranty 
of any kind, either expressed or implied, as to the accuracy of the information or the fitness of the 
information for any particular use. To the fullest extent possible under applicable law, CIHR and CRISM 
disclaim and will not be bound by any express, implied, or statutory representation or warranty 
(including, without limitation, representations or warranties of title or non-infringement). This 
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document is intended to provide guidance to facilitate substance use care. This guidance document 
is not intended as a substitute for the advice or professional judgment of a health professional, nor is 
it intended to be the only approach to the management of a clinical problem. We cannot respond to 
patients or patient advocates requesting advice on issues related to medical conditions. If you need 
medical advice, please contact a local health care professional.
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Detailed Summary – Disclosure of Interests for CRISM 
Rapid Response COVID-19 Supporting People Who Use 
Substances in Acute Care Settings during the COVID-19 
Pandemic (see Appendix 1 for conflict of interest policy)
In accordance with the Guidelines International Network’s Principles for Disclosure of Interests and 
Management of Conflicts (i), authorship committee members and external reviewers were asked to 
disclose all sources and amounts of direct and indirect (i.e., research support) remuneration from 
industry, for-profit enterprises, and other entities that could potentially introduce real or perceived 
risk of bias. In addition, authorship committee members and external reviewers were asked to report 
indirect sources of bias, such as academic advancement, clinical revenue, and professional or public 
standing that could potentially influence interpretation of research evidence and formulation of 
recommendations.
Of 30 authorship committee members and external reviewers, 14 acknowledged potential direct 
conflicts of interest. Of these, 10 acknowledged employment or consulting with organizations 
including academic institutions, hospitals/health authorities, professional or regulatory associations, 
HIV/AIDS foundations, community outreach agencies or federal funding agencies. Only one (an 
external reviewer) disclosed receiving research funding prior to guidance document involvement 
from a commercial entity (Gilead) that could theoretically benefit from guidance document 
recommendations. There was one authorship committee member with a commercial interest in the 
form of partial ownership of a medical clinic that provides treatment to people who use substances 
including opioid agonist treatment. On review, potential conflicts of interest were not deemed to be 
of sufficient weight or relevance to warrant exclusion from the guidance committee.
Most (23, 77%) authorship committee members and external reviewers disclosed potential indirect 
sources of bias (e.g., specialization in addiction medicine, advisory board and committee membership, 
involvement with acute care programs, provincial substance use treatment programs, previous 
guideline development, research interests). Of these, 6 acknowledged that they have publicly stated 
support for acute care treatment of PWUD.
In order to mitigate the risk of bias while maximizing the contributions of members in their respective 
areas of expertise, authorship committee members and external reviewers were reminded to 
consider any influential factors or sources of bias during the review process. Authors and reviewers 
with indirect potential sources of conflict contributed to review of sections related to their areas of 
expertise as well as the overarching guideline content to ensure that a broad range of clinical and 
academic specializations was adequately represented.
i.   Schünemann HJ, Al-Ansary LA, Forland F, et al. Guidelines international network: principles for disclosure of interests and management of 
conflicts in guidelines. Ann Intern Med. 2015;163(7):548-553.
Supporting People Who Use Substance in Acute Care Settings   | NATIONAL RAPID GUIDANCE  |   PAGE 9 
Acknowledgments
The committee acknowledges the assistance of the CRISM Node managers: Denise Adams (Prairies), 
Farihah Ali (Ontario), Nirupa Goel (BC), and Aissata Sako (Quebec/Atlantic).
This work was undertaken, in part, thanks to funding from the Canadian Institutes of Health Research 
(CIHR) CRISM Urgent Guideline Activities Related to COVID‑19.
PAGE 10  |   Supporting People Who Use Substance in Acute Care Settings  |  NATIONAL RAPID GUIDANCE
TABLE OF CONTENTS
A B B R E V I AT I O N S  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 2
1 . 0   K E Y  P O I N T S  O F  T H E  G U I DA N C E  D O C U M E N T  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 3
2 . 0   P U R P O S E  A N D  S CO P E  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 4
2 . 1   D e ve l o p m e nt   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 5
2 . 2   I n te n d e d  A u d i e n c e  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 6
2 . 3   B a c k g ro u n d  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 6
2 . 3 . 1   S p e c i f i c  r i s ks  re l a te d  to  COV I D - 1 9  a n d  s u b sta n c e  u s e  . . . . . . . . . . . . . . . . . 1 6
2 . 3 . 2   R i s ks  a s s o c i ate d  w i t h  h o s p i ta l i zat i o n  fo r  p e o p l e  w h o  u s e  
s u b sta n c e s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 7
3 . 0   P ROV I D I N G  C A R E  TO  P EO P L E  W H O  U S E  S U B S TA N C ES  I N  AC U T E  C A R E  
S E T T I N G S  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 9
3 . 1   A d d re s s i n g  S t i g m a  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 9
3 . 2   S c re e n i n g  a n d  a s s e s s m e nt  fo r  s u b sta n c e  u s e   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 9
3 . 3   H a r m  re d u c t i o n  a n d  Re co ve r y   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 0
3 . 4   Tra u m a  I n fo r m e d  C a re  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 0
3 . 5   COV I D - 1 9  s p e c i f i c  co n s i d e rat i o n s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 1
4 . 0   S U B S TA N C E  S P EC I F I C  R ECO M M E N DAT I O N S  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 2
4 . 1   G e n e ra l  C o n s i d e rat i o n s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 2
4 . 2   To b a c co  U s e  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 2
4 . 3   A l co h o l . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 3
4 . 4   C a n n a b i s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 4
4 . 5   O p i o i d s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 4
4 . 6   S t i m u l a nt s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 6
4 . 7   A d d re s s i n g  o n go i n g  s u b sta n c e  u s e  i n  h o s p i ta l  s e tt i n g s  . . . . . . . . . . . . . . . . . . . . . . . . 2 6
4 . 7 . 1   S a fe r  u s e  e q u i p m e nt  d i s t r i b u t i o n  i n  a c u te  ca re  s e tt i n g s  . . . . . . . . . . . . . . 2 7
4 . 7 . 2   S u p e r v i s e d  co n s u m p t i o n  s e r v i c e s  i n  a c u te  ca re  s e tt i n g s  . . . . . . . . . . . . . . 2 8
5 . 0   P R E V E N T I N G  PAT I E N T - I N I T I AT E D  D I S C H A RG ES  I N  COV I D - 1 9  P O S I T I V E  
PAT I E N T S  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 9
5 . 1   G e n e ra l  P r i n c i p l e s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 9
5 . 2   C o m fo r t  a n d  E nte r ta i n m e nt  re s o u rc e s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 9
5 . 3   C o n n e c t i o n  to  s u p p o r t s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 0
5 . 4   Pe e r  S u p p o r t  S e r v i c e s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 0
5 . 5   C o n n e c t i o n  to  s u b sta n c e  u s e  s u p p o r t s  a n d  re co ve r y  re s o u rc e s . . . . . . . . . . . . . 3 0
5 . 6   U s e  o f  n u rs i n g  a s s i s ta nt s  a n d  o t h e r  s u p p o r t  s ta f f  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 1
5 . 7   U s e  o f  t h e  P u b l i c  H e a l t h  A c t  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 1
Supporting People Who Use Substance in Acute Care Settings   | NATIONAL RAPID GUIDANCE  |   PAGE 11 
6 . 0   E N D  O F  L I F E  A N D  PA L L I AT I V E  C A R E  CO N S I D E R AT I O N S  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 2
6 . 1   D ef i n i t i o n  o f  p a l l i a t i ve  ca re  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 2
6 . 2   C o nve rs at i o n s  a n d  p l a n n i n g  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 2
6 . 3   Sy m p to m  m a n a ge m e nt  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 3
6 . 3 . 1   D ys p n e a  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 3
6 . 3 . 2   C o u g h  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 4
6 . 3 . 3   U p p e r  re s p i rato r y  s e c re t i o n s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 4
6 . 3 . 4   Fe ve r  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 4
6 . 3 . 5   Pa i n  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 5
6 . 3 . 6   D e l i r i u m  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 5
6 . 4   O t h e r  co n s i d e rat i o n s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 5
6 . 4 . 1   Pa l l i a t i ve  C a re  C o n s u l tat i o n  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 5
6 . 4 . 2   Pa l l i a t i ve  ca re  i n  o t h e r  s e tt i n g s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 6
6 . 4 . 3   Psyc h o l o g i ca l  a n d  g r i e f  s u p p o r t  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 6
7 . 0   A D D R ES S I N G  OT H E R  H EA LT H  N E E D S   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 7
7 . 1   M e nta l  h e a l t h  co n c e r n s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 7
7 . 2   S o c i a l  D e te r m i n a nt s  o f  H e a l t h  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 7
7 . 3   I m m u n i zat i o n s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 7
7 . 4   S c re e n i n g  fo r  S exu a l l y  Tra n s m i tte d  a n d  B l o o d  B o r n e  I n fe c t i o n s  . . . . . . . . . . . . 3 8
8 . 0   T R A N S F E R  O F  C A R E  TO  CO M M U N I T Y  P ROV I D E RS  AT  D I S C H A RG E  . . . . . . . . . . . . . . . . . 3 9
8 . 1   G e n e ra l  co n s i d e rat i o n s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 9
8 . 2   D i s c h a rge  to  h o m e  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 9
8 . 3   Tra n s fe r  to  a n  I n p at i e nt  A d d i c t i o n  Tre at m e nt  P ro g ra m  . . . . . . . . . . . . . . . . . . . . . . . . 4 0
8 . 4   Tra n s fe r  to  a n  e m e rge n c y  s h e l te r  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 0
8 . 4 . 1   A d a p te d  s h e l te r  ( a  s h e l te r  s e tt i n g  w h e re  p at i e nt s  a re  n o t  re q u i re d 
to  s e l f- i s o l ate )  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 0
8 . 4 . 2   M e d i ca l  I s o l at i o n  S h e l te r  ( s h e l te r  s e tt i n g  w h e re  p at i e nt s  a re 
re q u i re d  to  s e l f- i s o l ate )  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 1
8 . 5   D i s c h a rge  p re s c r i b i n g  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 2
A P P E N D I X  1   CO N F L I C T  O F  I N T E R ES T  P O L I C Y  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 4
A P P E N D I X  2 :  D I S C H A RG E  C H EC K L I S T  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 6
A P P E N D I X  3 :  O N L I N E  S U B S TA N C E  U S E  R ES O U RC E  L I S T I N G  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 8
A P P E N D I X  4 :  H EA LT H  C A N A DA  TO O L  K I T  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 1
R E F E R E N C ES  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 2
PAGE 12  |   Supporting People Who Use Substance in Acute Care Settings  |  NATIONAL RAPID GUIDANCE
ABBREVIATIONS
AUDIT: Alcohol Use Disorders Identification Test
AUDIT-C: Alcohol Use Disorders Identification Test - Consumption
BiPAP: Bilevel Positive Airway Pressure
CAGE: “Cut-Annoyed-Guilty-Eye Opener”; screening test for alcohol use
COVID-19: Novel Coronavirus disease of 2019
CPAP: Continuous Positive Airway Pressure
DAST-10: Drug Abuse Screening Test
DSM-5: Diagnostic and Statistical Manual of Mental Disorders, 5th Edition 
ESAS-r: Edmonton Symptom Assessment System Revised
HCV: Hepatitis C Virus
HIV: Human Immunodeficiency Virus
iOAT: Injectable Opioid Agonist Treatment 
MAID: Medical Assistance in Dying 
NRT: Nicotine Replacement Therapy 
OAT: Opioid Agonist Treatment 
PPE: Personal Protective Equipment 
SDM: Substitute Decision Maker
UPHNS: Urgent Public Health Need Site 
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1.0  Key points of the guidance 
document
• In the context of COVID-19, extraordinary measures are required to support people who 
use substances, minimize the spread of COVID-19 within their and other communities and 
ensure efficient use of acute care resources.
• People who use substances are at increased risk of negative health outcomes during the 
COVID-19 pandemic due to coexisting medical and mental health conditions, disruptions in 
drug and alcohol supply, and reduced access to addiction treatment, recovery supports, and 
harm reduction services such as sterile equipment and supervised consumption services.
• In order to reduce the risk of patient-initiated discharge in patients under investigation for, 
or with known, COVID-19, steps should be taken to identify patients with substance use 
disorders and to swiftly initiate evidence-based treatment, as well as aggressively manage 
withdrawal and cravings, in hospital settings. 
• Despite treatment initiation and other strategies to manage withdrawal and cravings, some 
patients may continue to use substances during hospital admission. In these cases, patients 
should be provided with access to sterile equipment, a place to safely dispose of used 
equipment, education about safer drug use during COVID-19, and an individualized safety 
plan to minimize the risk to themselves (e.g. unwitnessed overdose) and others.
• People who use substances with life-limiting illness related to COVID-19 should be offered 
a palliative care approach. A detailed opioid use history should be taken on all patients to 
guide therapy; for patients on opioid agonist treatment, collaboration should occur between 
the opioid agonist treatment prescriber and the physician managing end of life symptoms.
• Hospitalization should be viewed as an opportunity to address other patient specific 
health needs such as: mental health concerns; stabilizing the social determinants of health 
(e.g. providing or connecting patients to resources around housing, income supports, and 
medication coverage); providing immunizations; and, screening and treatment initiation for 
sexually transmitted and blood borne infections.
• Discharge planning should include consideration of the discharge location (home, addiction 
treatment program, adapted shelter, or medical isolation shelter). All patients should 
have follow up arranged with a prescriber (new or existing), a discharge pharmacy able 
to accommodate ongoing isolation requirements (if required), confirmed medication 
coverage, a take home naloxone kit, and an adequate supply of sterile drug use equipment 
(if required).
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2.0  Purpose and Scope
The World Health Organization declared the 2019 Novel Coronavirus (COVID-19) viral infection a 
pandemic on March 11, 2020. Canada has also been experiencing a crisis of opioid-related harm 
with more than 14,700 apparent opioid-related deaths between January 2016 and September 2019 
(1). This is superimposed on endemic high levels of morbidity and mortality from alcohol (2) and 
significant regional problems with methamphetamines (3). In addition, border closures related to 
COVID-19 have interrupted the supply of illegal drugs potentially worsening a drug market already 
prone to toxic contaminants (4,5). The intensity and harms associated with these simultaneously 
occurring events varies by province, and interventions must be tailored and prioritized to local 
context. The intersection of these multiple public health emergencies has the potential to magnify 
the harms already experienced by people who use substances as well as to overwhelm existing acute 
care resources (5).
In this context, extraordinary measures are required to support people who use substances, minimize 
the spread of COVID-19 within communities and ensure efficient use of acute care resources. In 
particular, insufficient and substandard care for people who use substances in acute care settings, 
while always unacceptable, now poses the additional risk of patient-initiated discharge potentially 
leading to community transmission of COVID-19.
The purpose of this national rapid guidance document is to support acute care hospital environments 
in providing evidence-informed care for people who use substances in the context of the COVID-19 
pandemic in Canada. The strategies discussed in this document are intended to help hospital based 
health care providers identify people in need of substance use related support early in their health 
care encounter, provide care based on best practices, and mitigate the risks of both substance use 
related harm and COVID-19 transmission during and after hospitalization.
Specifically, this document provides:
• An overview of the combined health risks associated with COVID-19 infection, substance use, 
and hospitalization
• An overview of general principles for providing care to people who use substances in acute 
care settings, including COVID-19 specific considerations
• Substance specific management recommendations in the setting of COVID-19
• Strategies for managing ongoing substance use in hospital settings
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• Techniques to minimize patient-initiated discharge prior to the completion of medical treatment
• End of life and palliative care considerations for people who use substances dying from COVID-19
• Suggestions for addressing other health and social concerns during hospitalization
• Guidance on seamless discharge to home, inpatient addiction treatment programs, and shelter 
settings
Readers should note that this document does not provide recommendations for medication dosing. 
Prescribers are encouraged to consult relevant clinical practice guidelines, specialist colleagues, or 
other trusted sources if unfamiliar with the indications, contraindications, drug interactions, side 
effects, and dosing for medications mentioned herein. It also does not provide guidance for patients 
requiring resuscitation or care in the intensive care unit.
2.1  DEVELOPMENT 
This guidance document on supporting people who use substances in acute care settings was 
developed to provide urgent advice in the context of the COVID-19 pandemic. Members of the 
authorship committee developed this document based on expert knowledge, scientific evidence, 
and a review of documentation from health authorities and other relevant organizations. The 
recently released document entitled, “Management of Substance Use in Acute Care Settings in 
Alberta: Guidance Document” also informed the development of this work and can be viewed as a 
complementary resource.
The urgent nature of this work required rapid development and dissemination of this guidance. 
This timeline and the continuing evolution of the knowledge base regarding COVID-19 precluded a 
thorough description of extant literature. However, where available, academic studies are cited in 
support of the expert advice offered herein. The guidance provided in this document is subject to 
change as new information becomes available. 
Readers should note that the intent of this document is to provide general guidance for supporting 
people who use substances in acute care settings across Canada rather than prescriptive procedural 
instructions. Hospital policies and procedures may vary by provincial/territorial jurisdiction. Readers 
should consult provincial/territorial health regulatory authorities for advice on navigating their own 
unique policy environments, as necessary. 
Note that a number of external organizations have produced relevant resources for supporting people 
who use substances. Where possible, we have linked to external documents or websites which may 
be useful for readers of this guidance; at the time of publication, all links were confirmed to be active.
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2.2  INTENDED AUDIENCE
The target audience for this national rapid guidance document includes both clinical and non-clinical 
staff caring for people who use substances in acute care hospital settings. The information contained in 
this document may also be relevant for senior operational and medical leaders, policy makers, public 
health authorities, those operating shelters for people who use substances, groups representing 
people who use substances, and people with lived and living experience of substance use.
2.3  BACKGROUND
Only a fraction of people who consume alcohol, cannabis, or illegal drugs experience substance-
related harm or meet diagnostic criteria for a substance use disorder. Yet every day in Canada, more 
than 400 people are hospitalized because of harm from alcohol or drugs - more than for heart attacks 
and strokes combined. Alcohol contributes to more than half of these hospital stays (2). Substance 
use can result in morbidity and mortality from physical trauma, acute and chronic toxicity, blood 
borne and pathogenic infections (e.g. HIV, HCV), as well as other health conditions (6,7). Harms can 
arise from the effect of the substances themselves, or from the circumstances surrounding use such 
as unsafe injection practices, using alone, and consuming non-beverage alcohol, or contaminated or 
toxic substances such as fentanyl and other drugs purchased on the illegal market (1,6,7).
2.3.1  Specific risks related to COVID-19 and substance use
People who use substances may be at increased risk of related harm during the COVID-19 pandemic. 
Challenges coping with stress and anxiety caused by threats to both lives and livelihoods, and physical 
distancing recommendations, may lead to an increase in drug and alcohol use. Disruptions in access 
to alcohol among people with alcohol use disorders could lead to serious medical complications, 
including seizures and death. Disruptions in access to treatment and recovery support for people 
with substance use disorders may increase the risk of relapse. Disruptions in the illegal drug supply 
may result in increasing levels of contamination and increase the likelihood that people who use 
substances will experience medical complications associated with withdrawal or toxicity (5). Those 
who rely on harm reduction programs to obtain sterile equipment, naloxone kits, and supervised 
consumption services may be unable to access the care they need due to program closures or 
COVID-19 related capacity constraints (8). Inability to access needed equipment and services may 
lead to an increased risk of blood borne and other pathogenic infections among people who inject 
drugs through unsafe injection practices such as the reuse of equipment (9,10).
People with substance use disorders are more likely to be structurally vulnerable and to experience 
comorbid mental health disorders, criminalization, stigma, homelessness, and reduced social and 
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vocational functioning relative to members of the general public (11). Structural vulnerability is "an 
individual's or a population group's condition of being at risk for negative health outcomes through 
their interface with socioeconomic, political, and cultural/normative hierarchies" (12, p.17). These 
factors dramatically increase the risk of negative health outcomes in people with substance use 
disorders. This is especially true for those who are experiencing vulnerable housing or homelessness 
and those who rely on higher-risk income generating activities such as sex work, panhandling, 
dealing, or informal recycling, that require prolonged or close contact with many others (13–17). 
While the effects of structural vulnerability on COVID-19-related health outcomes requires further 
investigation, it is nevertheless prudent to attempt to reduce health and social inequities in the context 
of a pandemic. Sleeping in outdoor encampments or shelters makes practicing physical distancing or 
recommended hygiene practices very challenging (18). A change or reduction in community based 
services (e.g. loss of shower facilities and safe storage options) also creates challenges. In addition, 
individuals that choose to comply with Public Health mandated isolation orders in settings such as 
temporary medical isolation shelters may not have access to the full range of supports available in 
community settings, such as supervised consumption services. Lastly, for some, the risk of COVID-19 
infection may be perceived to be less than the risk of their usual day-to-day activities, and thus 
compliance with physical distancing may be a lower priority.
2.3.2  Risks associated with hospitalization for people who 
use substances
People who use substances, especially those with substance use disorders, are more likely to 
experience acute health conditions that require immediate medical intervention and, compared to 
members of the general population, present to acute care settings for treatment more frequently 
(19,20). Rates of COVID-19 infection and related hospitalization amongst people who use substances 
are currently unknown, however, substance use disorders commonly occur alongside other comorbid 
conditions (e.g. chronic respiratory illnesses) that may increase the risk of severe outcomes related 
to COVID-19 in this patient group. People with a mental health disorder and co-existing substance 
use disorder may have more difficulty adhering to isolation precautions (21). Some symptoms of 
COVID-19, such as chills, sweating, rhinorrhea, and muscle aches, may be similar to withdrawal 
symptoms. Furthermore, consumption of certain substances may increase the user's risk of becoming 
seriously ill from COVID-19. Effects of opioids, benzodiazepines, and alcohol, all of which reduce the 
respiratory drive, may be exacerbated by COVID-19 infections. Smoking drugs such as crack cocaine, 
methamphetamines, and cannabis, may worsen respiratory symptoms (22–24).
Acute care hospitals can be viewed as a ‘risk environment’ for people who use substances, and in 
some cases, hospitalization may actually increase health and social harm experienced by members 
of this population (25). Substance use by patients in hospital may occur in patients who meet DSM-5 
criteria for a substance use disorder, or for various reasons, including: relief of inadequately managed 
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pain or withdrawal symptoms, to minimize the symptoms of anxiety or boredom, or out of desire 
or habit (25,26). Acute care staff may attempt to deter ongoing substance use through formal and 
informal sanctions that include changes to care or increased surveillance (25,27,28). People who use 
drugs have described being less able to practice harm reduction strategies (e.g. using sterile injection 
equipment) while hospitalized. Thus, due to a combination of factors, people who use substances are 
more likely than members of the general population to experience poor hospital outcomes including 
involuntary discharge, leaving against medical advice, and lengthy and costly readmissions (27,29,30). 
Fostering an environment of open communication where safety concerns related to ongoing drug use 
can be discussed is important.
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3.0  Providing care to people who 
use substances in acute care 
settings
3.1  ADDRESSING STIGMA
Stigma is the act of “showing discrimination, judgment and/or isolating and stereotyping others” (31) 
and frequently compounds and intersects with racism and gender bias. Stigma is a major barrier to 
healthcare access and can contribute to feelings of shame, blame, isolation, and guilt (32). People 
who use substances often encounter stigma when accessing acute care (33–36). This can include 
overt discrimination, such as hurtful or derogatory comments, or negative body language, such as 
avoiding eye contact. Stigma can also be subtle and may include ignoring requests for care or refusing 
to make appropriate referrals (32). Eliminating stigmatizing language is one simple way by which 
stigma can be reduced. This includes avoiding terms like ‘addict,’ ‘junkie,’ ‘get clean’, etc. and adopting 
neutral and person-centred language like ‘people who use substances’ or ‘patient with a substance 
use disorder,’ ‘person in recovery,’ instead. Further, healthcare staff should advocate on behalf of 
people who use substances if they witness them being spoken to or treated in a disrespectful way 
and educate others about the importance of reducing stigma. Education alone, however, is likely not 
enough to change stigmatizing practice and should be accompanied by practical experiences and/or 
opportunities to observe positive role models.
During COVID-19, infection control measures implemented by the hospital may be perceived as 
stigmatizing and therefore a clear explanation and rationale for all pertinent infection control 
measures should be provided to the patient upon admission. As changes to hospital policies and 
procedures occur, these also must be clearly communicated. In addition, patients should be asked 
if they anticipate any challenges to being able to comply with these measures so that these can be 
addressed.
3.2  SCREENING AND ASSESSMENT FOR SUBSTANCE 
USE 
Screening acute care patients for substance use is essential to providing appropriate care. The CAGE, 
AUDIT, and AUDIT-C tools are commonly used to screen for alcohol-use related harms (37,38) and 
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the DAST-10 can be used to screen for substance-use related harms (39). Another option is the NIDA 
Quick Screen, which asks about past year use of alcohol, tobacco, prescription drugs for non-medical 
reasons, and illegal drugs (40). When inquiring about substance use, clinical staff may receive more 
honest and detailed answers if they reassure patients that their goal is to provide them the best care 
possible, discuss the patient’s substance use in private, and emphasize that the information provided 
by patients is confidential.
3.3  HARM REDUCTION AND RECOVERY 
Harm reduction is an umbrella term for both a philosophy of care and a set of interventions that aim 
to reduce harms associated with consuming substances without making the receipt of care contingent 
on reducing or stopping substance use. Substance use can occur along a continuum from beneficial to 
harmful, and people deserve non-judgmental care that supports their rights to autonomy and dignity 
regardless of where they fall on that continuum. Under a harm reduction approach, modifying risks 
associated with unsafe drug use practices or settings takes precedence over enforcing abstinence.
Recovery is an active process of ongoing growth, improving quality of life and connectedness (41). 
People in recovery, or those starting their recovery journey, may need unique supports in the context 
of COVID-19. Access to addiction treatment and recovery supports, as well as other health and social 
services are based on each individual’s self-defined needs and goals.
3.4  TRAUMA INFORMED CARE
At times, individuals can experience events (e.g. child neglect and abuse, witnessing and experiencing 
violence) which overwhelm their ability to cope (42,43). These traumatic events can be direct or 
indirect and can have significant acute and prolonged psychological and physiological impacts, 
including an increased risk of substance use disorders (43,44).
A trauma-informed approach to acute care recognizes "the need to respond to an individual's 
intersecting experiences of trauma, mental health, and substance use concerns...in all aspects of 
service delivery and places priority on the individual's safety, choice, and control" (42). Foundational 
to this approach is ensuring that individuals experience no further trauma and that they make 
informed choices that feel safe to them (42). In acute care settings, this could mean asking patients 
with substance use disorders about their priorities regarding their care or asking patients how staff 
can make their hospital stay more comfortable (45). 
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3.5  COVID-19 SPECIFIC CONSIDERATIONS
COVID-19 has necessitated the implementation of widespread and sweeping public health efforts 
across the globe. These efforts are critical to controlling the pandemic and have required individual, 
municipal, provincial and federal cooperation on a large scale. Given the magnitude of change required, 
it is not surprising or inappropriate that specific populations may require special consideration in 
response to urgently implemented practice changes such as physical distancing, restricted visitor 
access and other measures required to reduce the risk of outbreaks in acute care settings.
COVID-19 related changes to the hospital environment may compound existing challenges people 
who use substances face while hospitalized. Early involvement of an addiction medicine consult team 
(if available) or expert consultation via a provincial consultation line is strongly recommended. 
Those who test positive for COVID-19, are under investigation for COVID-19, or a close contact 
of someone with COVID-19, must isolate while in hospital and have visitor restrictions. Due to 
widespread visitor restrictions at many hospitals, even patients who test negative for COVID-19 or are 
not admitted with any symptoms of COVID-19 may be unable to have visitors. Enforced isolation may 
contribute to feelings of stigmatization or trigger memories of historical trauma. A clear explanation 
of the reasons for isolation and its associated requirements is critical. Any changes to hospital 
procedures that occur during hospitalization should also be communicated quickly and in a patient-
centered manner. Isolation precautions may also disrupt access to alcohol or drugs (25,26). As a result, 
patients who use substances may be at risk of experiencing potentially serious withdrawal symptoms, 
or acute toxicity if using alone in their rooms. Withdrawal symptoms may confound monitoring 
for COVID-19 related symptoms. Additionally, those who experience a period of abstinence while 
hospitalized may develop reduced tolerance and be at increased risk of overdose and death if they 
return to substance use post-discharge (46–48). Evidence-based treatment for those with substance 
use disorders should be initiated and continued after discharge whenever possible. People who use 
substances may also struggle to communicate with their friends and family while in hospital and 
those who are structurally vulnerable may lack access to a cell phone for communication. Patients 
who earn their income through informal means may require income support or income replacement, 
particularly if they are supporting a loved one as well. In these cases, consideration could be given to 
providing financial compensation for treatment adherence (49,50). 
Due to a combination of factors, some patients may experience increased emotional and physical 
distress while hospitalized, further exacerbating ongoing substance use as well as precipitating 
patient-initiated discharge. People with substance use disorders are also more likely to have an acute 
mental health condition (e.g. psychosis or suicidality). It is important to perform a mental health 
assessment so as not to erroneously attribute symptoms to another cause thus resulting in missed or 
undertreated mental health concerns.
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4.0  Substance Specific 
Recommendations
4.1  GENERAL CONSIDERATIONS
While each treatment plan must be individualized to patient and provider circumstances, some 
general considerations include the following:
• Coordination of medication dosing times and other patient care activities to reduce the 
frequency of patient-facing contact and personal protective equipment (PPE) usage in patients 
who are COVID-19 positive or under investigation for COVID-19
• When initiating new treatments in hospital, consider the availability of ongoing treatment in 
the patient’s local community
• All patients at risk of having an unintentional opioid overdose should have an as needed 
naloxone order on their chart as well as be provided with a naloxone kit upon admission
• All patients should be provided with tailored education about safer substance use in the 
setting of COVID-19 (more information can be found in the CRISM National Rapid Guidance 
Document ‘Supporting people who use substances in shelter settings during the COVID-19 
pandemic’)
4.2  TOBACCO USE
Smoking cessation should be encouraged for all patients admitted with a respiratory illness, including 
COVID-19. Smoking has been associated with COVID-19 progression (51,52). Nicotine replacement 
therapy (NRT) products (including transdermal patches, lozenges, gum, inhalers, and oral sprays) are 
generally safe and increase smoking cessation rates. Choice of product depends on availability and 
patient preference although combining two forms of NRT is associated with higher rates of smoking 
cessation (53). First line medication options include varenicline and bupropion SR, both of which 
increase rates of smoking cessation during hospitalization. Regardless of whether medication is 
initiated, patients may still benefit from NRT - which is safe to combine with pharmacotherapy (54) 
- to help them cut down on their use, or to help manage cravings and withdrawal symptoms if they 
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are unable to smoke as frequently as they would like due to isolation precautions. Ideally, patients on 
isolation precautions should always have at least two forms of NRT available at the bedside. 
4.3  ALCOHOL
Alcohol use disorder is a risk factor for leaving hospital against medical advice and readmission within 
15 days (29,55). In order to decrease this risk, both alcohol withdrawal and ongoing cravings to 
consume alcohol need to be appropriately managed in hospitalized patients.
Alcohol withdrawal is a life-threatening medical condition requiring urgent management to prevent 
sequelae such as cardiac arrhythmias, seizures, and delirium. Withdrawal typically presents within 
6-72 hours after a patient’s last drink and can be present when alcohol levels are still elevated. The 
Prediction of Alcohol Withdrawal Severity Scale (PAWSS) can be used to help identify which patients 
may be most at risk of developing severe symptoms (56). Benzodiazepines are the standard of care 
for managing withdrawal and a symptom-triggered approach using the Clinical Institute Withdrawal 
Assessment for Alcohol Withdrawal (CIWA-Ar) (57) can be used to guide when benzodiazepines are 
indicated. However, in the setting of COVID-19, use of regularly scheduled benzodiazepines or use of 
other medication adjuncts could be considered in order to minimize healthcare worker contact and 
conserve PPE in COVID-19 positive patients or those under investigation for COVID-19. Care must also 
be taken to avoid the harms associated with benzodiazepine toxicity, particularly in patients with an 
overlapping acute medical illness such as COVID-19 (58). Intravenous thiamine replacement should 
also be provided.
Even if alcohol withdrawal has been appropriately treated and resolved, cravings may persist. First 
line medication options such as naltrexone and acamprosate have been found to assist those with 
alcohol use disorder to reduce intake, support abstinence, and delay time to first relapse. Second line, 
off-label medications include gabapentin, topiramate, valproic acid and others (59,60).
In situations where an abstinence-based management plan is declined, or when a patient continues 
to use alcohol while in hospital (or is likely to continue to use alcohol), and/or when ongoing 
alcohol use has previously interfered with an individual’s ability to address their health concerns, 
the provision of alcohol via a managed alcohol program should be considered. This is particularly 
important in patients with COVID-19 where patient-initiated discharge is likely to put the patient 
and others in the community at risk. In addition, patients with confirmed, or under investigation for, 
COVID-19 who have a history of severe withdrawal requiring previous intensive care unit admission 
should also be considered for an inpatient managed alcohol program so as to avoid the potential 
need for intubation due to severe withdrawal. The amount and frequency of alcohol required will 
need to be determined based on the patient’s reported use and a dosing schedule determined. When 
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determining dosing frequency, a balance must be found between frequent dosing requiring patient-
facing contact and use of PPE, and management of withdrawal and cravings. An assessment should 
be done prior to administration to prevent over-intoxication and doses are typically consumed under 
supervision [see 31, Appendix B - Sample Alcohol Order] (31,61). A managed alcohol program may 
reduce the daily amount of alcohol the patient consumes and assist with stabilization. At the time 
of discharge and following completion of isolation requirements, patients should be offered various 
options for ongoing treatment including managed alcohol programs in the community (if available), 
detoxification programs, and/or other recovery supports.
4.4  CANNABIS
First-line treatment for cannabis use disorder includes psychosocial interventions such as cognitive-
behavioral therapy (CBT), motivational enhancement therapy (MET), or contingency management 
(62); if available, consideration should be given to offering these via virtual platforms in hospital, if 
appropriate. There is currently no evidence to support using other cannabinoid preparations for the 
treatment of cannabis use disorder. For patients with cannabis use disorder who wish to attempt 
cessation while admitted to hospital, a trial of gabapentin, nabiximols (if available), or nabilone may 
be warranted. A small research study showed that gabapentin in doses of 1200 mg daily, in addition to 
psychosocial support, was associated with reduced cannabis use (63); however, gabapentin should be 
used with caution in patients at risk for respiratory depression or taking other sedating medications. 
Evidence on the use of nabiximols, a cannabis whole-plant extract, is mixed (64,65) though it may 
be better tolerated than gabapentin. A small study using nabilone to treat withdrawal and reduce 
cannabis use showed some encouraging results (66). The use of gabapentin, nabiximols, or nabilone 
is considered off-label use.
Patients with cannabis use disorder on isolation precautions, or those without a steady supply of 
cannabis, may be at risk of withdrawal symptoms which can include irritability, anxiety, and sleep 
disturbances. In some settings, patients may be able to use their own (or hospital provided) edible 
cannabis products. Most symptoms are mild and, if needed, treatment can be provided to target 
specific symptoms (e.g. using trazodone at night for insomnia). More severe symptoms could warrant 
treatment with off-label options such as gabapentin, nabilone, or nabiximols (if available) (67).
4.5  OPIOIDS
Opioid agonist treatment (OAT) is considered the standard of care for people with opioid use disorders 
(68). Buprenorphine/naloxone is the preferred first-line treatment and methadone is considered an 
alternative first-line treatment. Ideally, patients with untreated opioid use disorder admitted to acute 
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care environments would have rapid access to health care providers able to initiate and titrate these 
medications. A patient-centered approach to titration (i.e. consideration of the patient’s perception of 
adequacy of OAT dose) is critical to achieving the expected health benefits (69). Immediate treatment 
initiation, along with withdrawal management, is critical for preventing premature discharge of 
patients under investigation for, or with confirmed, COVID-19. 
Other expert-led treatments for opioid use disorder include slow release oral morphine (SROM) and 
injectable opioid agonist treatment (iOAT). SROM involves oral administration of opened, witnessed 
capsules of 24-hour extended-release morphine (70). iOAT involves patient self-administration 
of prescribed diacetylmorphine or hydromorphone intravenously (or intramuscularly) multiple 
times per day under health care provider supervision (71). For patients unable to stabilize on first-
line treatments, these alternative treatment options should be considered and initiated whenever 
possible (71,72). Health care providers working in hospitals without addiction medicine consult teams 
may be able to access advice through provincial consult lines or by consulting addiction medicine 
specialists in the community.
When evidence-based treatments are being titrated, or are not effective, not available, or declined 
by the patient, an alternative harm reduction approach should be employed. This involves titrating 
full-agonist opioids (typically observed doses of liquid oral solution morphine or hydromorphone) 
to manage withdrawal and cravings. If liquid medications are not effective, consideration should 
be given to nursing administered subcutaneous, intravenous, or transdermal opioids as a next step 
(31). Under no circumstances should patients be forcibly detoxified from opioids as this is considered 
harmful and increases the risk of death post-discharge (68). Before initiating opioids for this purpose, 
discharge planning should be considered including whether referral to another provider will occur, 
the medication will be tapered, or a short-term supply provided.
Despite all the above measures, some patients may continue to leave hospital for periods of time 
to procure and/or consume illegal opioids. For patients who are COVID-19 positive, or under 
investigation for COVID-19, this places the patient and others in the community at risk. In these 
exceptional situations, provision of a prescribed supply of opioids for patients to self-administer 
under nursing supervision with sterile equipment (e.g. parenteral hydromorphone administered by 
the patient intravenously or intramuscularly, or hydromorphone 8 mg tablets which can be crushed 
for intranasal use) may be considered (31). In these cases, consultation with an addiction medicine 
specialist is advised. In some provinces, there may be recommendations to provide medications for 
unsupervised use as well (73). Please see the Health Canada Safer Supply Toolkit for more information 
(Appendix 4). Patients should continue to be offered all forms of OAT throughout their admission and, 
although this type of prescribing may not be possible after discharge, patients should be connected 
to a prescriber for follow up. An informed consent discussion with the patient outlining the risks, 
benefits, and alternative treatments that have been discussed should be documented on the chart.
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4.6  STIMULANTS
There are currently no pharmacotherapies that have been shown to be effective for the treatment of 
stimulant use disorders, however research is ongoing (74). Stimulant induced psychosis may require 
administration of benzodiazepines and/or anti-psychotics. Stimulant withdrawal can present as 
hypersomnolence, anxiety, difficulty concentrating, and irritability. Withdrawal is typically mild and 
medications can be offered to address specific symptoms. Where available, connection to contingency 
management programs and addiction counselling should be considered (75).
For patients with ongoing harms related to stimulant use during hospital admission, a prescribed supply 
of stimulants can be considered. Prescribing stimulants may help to reduce the risk to the patient 
and the community from the risks associated with the illegal drug market (including contamination 
of stimulants with high potency synthetic opioids), as well as the activities required to procure 
substances which facilitate the spread of COVID-19. Medications such as dextroamphetamine SR, 
methylphenidate IR, or methylphenidate SR (all off-label use) could be considered for this purpose, but 
remain unstudied and should be considered strictly a harm reduction measure (73). For patients with 
a history of a mental health disorder, especially psychosis or mania, or those who are hospitalized for 
mental health reasons, the risks and benefits of this type of approach should be carefully considered 
before prescribing a psychostimulant medication. An informed consent discussion with the patient 
outlining the risks, benefits, contraindications, and alternative treatments that have been discussed 
should be documented on the chart.
4.7  ADDRESSING ONGOING SUBSTANCE USE IN 
HOSPITAL SETTINGS
Despite offering a full spectrum of evidence-based treatments as well as other prescribed medication 
options, some patients may still continue to use substances during their hospital admission. In these 
situations, concerted efforts should be made to ensure that the risks of infection (e.g. from the use 
of contaminated or reused injection equipment), death, and COVID-19 transmission are minimized. 
At a minimum and throughout their hospitalization, all patients should have access to safer use 
equipment, a way to safely dispose of used equipment, and a naloxone kit. A harm reduction and 
trauma informed approach should be used to inform the delivery of care. Creating an environment 
where patients feel comfortable disclosing ongoing injection drug use to their health care team may 
help to identify the patients at highest risk of unintentional overdose and those most in need of 
substance use related support. All patients, whether or not they can abstain from substance use, 
deserve respect, compassion, and treatment for their medical condition(s). 
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Overdose events are expected to increase as COVID-19 related disruptions in the drug supply chain 
lead to increased toxicity in the illegal drug market (4,5). Hospitals should prepare to experience an 
increase in unintentional opioid poisoning events on hospital campuses. These may involve patients, 
visitors, and/or staff. Strategies to consider include: performing overdose simulations in patient 
care and public areas; ensuring availability of naloxone and appropriate PPE across the site and 
across disciplines (including protective services team members); and, reviewing safety of single use 
washrooms available for public use. Those likely to respond to overdoses on hospital property should 
be updated on changes to local resuscitation guidelines designed to reduce the risk of COVID-19 
transmission (e.g. the use of N95 respirators for performing cardiopulmonary resuscitation or 
bag-valve mask ventilation).
4.7.1  Safer use equipment distribution in acute care settings
Harm reduction programs which provide sterile syringes and other equipment substantially reduce 
rates of HIV transmission, have no significant unintended consequences, and are cost effective (76–78). 
These programs are based on the fundamental principles of harm reduction and have been shown 
to engage individuals in primary care and substance use treatment programs as well as reduce the 
frequency of injection drug use and other complications (e.g. abscesses). Patients who are admitted 
to hospital should have easy access to sterile injection equipment, including syringes, alcohol swabs, 
tourniquets, filters, cookers, sterile water, and vitamin C (to break down any tablets). This equipment 
can be ordered from specialized distributors or possibly obtained from local community-based harm 
reduction service providers. Harm reduction education about safer drug use, including avoidance of 
groin and neck veins, and any peripherally or centrally inserted catheters, should also be provided. It 
is important to provide ready access to sharps containers and instruction on how to safely dispose of 
used equipment (77).
For more information on equipment distribution refer to:
• Best Practice Recommendations for Canadian Harm Reduction Programs that Provide Services 
to People who use Drugs and are at Risk for HIV, HCV, and Other Harms: Part 1; Working Group 
on Best Practice for Harm Reduction Programs in Canada.
• Best Practice Recommendations 2 for Canadian Harm Reduction Programs that Provide Service 
to People who use Drugs and are at Risk for HIV, HCV, and Other Harms; Working Group on 
Best Practice for Harm Reduction Programs in Canada.
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4.7.2  Supervised consumption services in acute care 
settings
Embedded supervised consumption services in acute care hospitals have the potential to improve 
safety and engage patients in addiction treatment (79). Hospitals responding to opioid poisoning 
events on their campus should consider opening an Urgent Public Health Need Site (UPHNS) or 
offering a bedside supervision model. A legal exemption is only required for the supervision of illegal 
(non-prescribed) substances. Information on how to obtain an exemption and set up supervised 
consumption services can be found in a companion document in CRISM’s national rapid guidance 
series, Supporting people who use substances in shelter settings during the COVID-19 pandemic. 
Information about how to operate these sites safely during COVID-19 can also be found in this 
companion document. Reduced access to community-based supervised consumption services due to 
the physical distancing requirements of COVID-19 may also prompt consideration of expanding any 
hospital-based UPHNS or supervised consumption sites to include access for the general public. 
If supervised use is not possible, steps should be taken to identify patients at risk of unintentional 
overdose. Developing an individualized safety plan to minimize the risk of unwitnessed overdose 
during admission is warranted especially for patients with visitor restrictions who will be more likely to 
consume substances alone. Education on safer use practices during COVID-19 should be provided to 
all patients and could include information such as virtual supervision methods, strategies to minimize 
contact with others, and recommended hygiene practices (not sharing equipment, preparing drugs 
yourself, washing hands) (please see Appendix 3: Online Substance Use Resource Listing for more 
information).
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5.0  Preventing Patient-Initiated 
Discharges in COVID-19 Positive 
Patients
5.1  GENERAL PRINCIPLES
People who use substances are more likely to leave hospital against medical advice (80). Patient-
initiated discharges increase morbidity, mortality, and health care system costs. In addition, in the 
context of communicable diseases such as COVID-19, premature discharge against medical advice of 
a patient with confirmed or suspected COVID-19 has the potential to further exacerbate community 
spread of the virus during an outbreak. It is therefore critical to pre-empt with measures that reduce 
premature discharge. Immediately upon admission, efforts should be made to identify what would 
be helpful to support treatment completion, as well as patient-identified barriers. This may include 
things like the need to take care of a loved one or pet, concerns around unattended belongings, the 
need to maintain or secure housing, court or custody proceedings, and unmanaged withdrawal and/
or cravings. Working together to identify the goals of the admission, and expectations on both sides, 
may help to create an open and collaborative relationship from the start.
5.2  COMFORT AND ENTERTAINMENT RESOURCES
Patients on isolation precautions for COVID-19 or other infections may be asked or required to 
remain in their rooms for long periods of time. This can be difficult for anyone, particularly those 
with comorbid anxiety, depression, post-traumatic stress disorder or attention deficit hyperactivity 
disorder. In addition, some people who use substances may have a history of incarceration and/or 
past traumatic experiences involving coercive admissions and confinement. Isolation requirements 
for COVID-19 should be considered in this context and implemented via the least restrictive means 
and in a way that provides the most comfort. If possible, patients should have access to entertainment 
resources; for those unable to access through other means, the hospital can consider supplying as a 
way to facilitate engagement in care. Some examples include free television, access to tablets, music, 
reading materials, and art supplies. Some individuals may desire extra food portions, or have specific 
dietary requests, which, if accommodated, may increase overall comfort in hospital. Working with 
the infection prevention and control team to ensure compliance with local guidelines is important.
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5.3  CONNECTION TO SUPPORTS
During COVID-19, access to visitors at most hospitals is severely limited. This makes it difficult for 
patients to connect to family, friends, and existing community supports (e.g. an Alcoholics Anonymous 
sponsor, housing worker, addiction counsellor etc.) during an extremely stressful time. In addition, 
some patients may not have a phone and access to shared phones in the hospital unit may be limited 
due to infection prevention and control measures. In these situations, the provision of tablets and/or 
cell phones for patient use during hospitalization has the potential to reduce isolation, improve well-
being, and facilitate ongoing connection to existing supports. For example, many community-based 
peer support programs have moved to a virtual format so with access to the appropriate technology, 
some patients may be able to participate in their usual recovery activities even while in hospital or on 
isolation precautions.
In addition to permitting ongoing connection to existing supports, technology may also be used to 
connect patients to new health care providers and community supports. With many services moving 
to virtual care delivery models, patients could now potentially use hospital provided technology to 
meet a new primary care provider, addiction counsellor, or recovery coach virtually prior to hospital 
discharge. These platforms may also be used to connect patients to online cognitive behavioural 
therapy and mental health resources during and after admission.
5.4  PEER SUPPORT SERVICES
Emotional support can be provided by a trained peer support worker to a patient where a shared 
common experience, such as a mental health challenge or illness, exists. Provision of peer support 
may be particularly important in stressful times and when access to visitors is restricted. Hospital 
employed peer support workers who can provide in-person support or virtual access to peer support 
workers in the community may be helpful for patients coping with the combined stresses of a 
substance use disorder and COVID-19. More information about peer support can be found at Peer 
Support Canada (https://peersupportcanada.ca/).
5.5  CONNECTION TO SUBSTANCE USE SUPPORTS 
AND RECOVERY RESOURCES
Where possible, patients should have access to substance use supports and recovery resources. These 
can either be in person (such as hospital employed addiction counsellors), via virtual connection 
to community-based programs, or via hospital-community partnerships that offer a hybrid model. 
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Emergency department visits and hospital admissions have been identified as a key point of contact 
with the health care system for individuals who use substances and an overlooked opportunity to 
initiate addiction treatment (81–83).
5.6  USE OF NURSING ASSISTANTS AND OTHER 
SUPPORT STAFF
Some patients may have difficulty complying with infection prevention and control guidelines. This 
may be due to a number of factors, including but not limited to: untreated and/or unidentified 
substance use concerns; cognitive impairment; and, mental health concerns. Early identification and 
mitigation of specific issues should be a top priority for health care providers in the acute care setting. 
This is particularly important in the context of a pandemic to facilitate maintenance of isolation 
and prevention of disease transmission. In some cases, and if within scope of practice and utilizing 
recommended PPE, a nursing assistant or other team member who can remain with the patient may 
be helpful, particularly if patients require frequent reminding, redirection, or accompaniment off unit.
5.7  USE OF THE PUBLIC HEALTH ACT
In extreme cases, patients who are confirmed to be COVID-19 positive and are unable to comply with 
isolation requirements may require apprehension under the relevant provincial, territorial or federal 
Public Health Act. This will require collaboration and consultation with the local Medical Officer of 
Health. Each case will require a balance between respecting individual rights and maintaining public 
health and safety. When these patients also require admission to acute care, every effort should be 
made to ensure that substance use related concerns are identified and managed.
Patients with COVID-19 who are unable to comply with isolation requirements in shelter settings 
may require transfer to acute care or another facility where more supports are available. Proactively 
developing transfer of care procedures and identifying vehicles suitable for the medical transport of 
people with COVID-19 will minimize the risk of community transmission.
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6.0  End of life and palliative care 
considerations
6.1  DEFINITION OF PALLIATIVE CARE
Palliative care involves the relief of suffering (physical, emotional, spiritual and existential), and 
focuses on quality of life in the setting of life-limiting illness (84). The intent is to provide ‘whole 
person’ care in alignment with the patient's goals and values. Palliative care is not the domain of any 
specific team but rather an approach that can be employed by all healthcare professionals. Specialist 
palliative consult teams remain ready to help provide assistance and advice for refractory symptoms 
and for those that require more specialized care. Advocates believe that palliative care should be a 
human right, but there is evidence that facing a life-limiting illness can actually increase inequities 
particularly for those that are structurally vulnerable (85). A multidisciplinary and collaborative 
approach to care is essential for equitable delivery of palliative care.
6.2  CONVERSATIONS AND PLANNING
Goals of care conversations should occur in an iterative manner and, if possible, with a healthcare 
provider with whom the patient already has a trusting relationship. Patients focused on surviving and 
living in the present moment may be more reluctant to discuss these topics. Evidence has shown that 
with appropriate intervention a high rate of advanced care directives can be completed for those who 
are chronically homeless (86).
In the setting of a more acute illness and presentation to acute care, conversations about goals 
of care may need to be readdressed. Again, having healthcare teams with whom the patient has 
a relationship present, even virtually, can be very helpful. Both collaborative and trauma informed 
approaches are needed. Tools such as the Serious Illness Conversation Guide (87) may be helpful and 
provide patient-tested language to help guide such conversations.
Substitute decision-makers (SDM) are consulted if the patient is not able to participate in discussions 
regarding goals of care. If a SDM has not been designated and there is no clear family contact, the 
office of the Public Guardian (or provincial/territorial equivalent) may need to be involved, but this 
process takes time. If time will not allow for the involvement of a Public Guardian’s office, it may be 
helpful to involve another team (such as palliative care) or a second physician to review the case and 
assist in making decisions regarding appropriate medical intervention.
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Past experiences, including lived experience, systemic discrimination and loss of loved ones, may 
cause reluctance to discuss end of life and acceptance of a palliative care approach. Patient-centered 
care with provision of best possible care will help mitigate fears of abandonment or receiving 
substandard care. If comfort care is desired, the patient’s goals and values are central to guide care.
6.3  SYMPTOM MANAGEMENT
Symptoms anticipated for patients with COVID-19 include dyspnea (along with associated anxiety), 
cough, upper respiratory secretions, fever, pain and delirium. Whenever possible, treatment for 
the underlying cause should be optimized if it is within the patient’s goals of care. Collaboration 
should occur with allied care providers including nursing, spiritual care, cultural liaison departments, 
psychology, social work, infection prevention and control, and others. No one person or role can 
address and alleviate all the aspects of suffering experienced by patients. Nearing the end of life 
brings a desire to reconnect with spiritual and/or cultural roots for some patients; for others this may 
not be the case (88,89). Many symptoms are subjective in nature, so assessment tools such as the 
Edmonton Symptom Assessment System Revised (ESAS-r) are helpful to follow symptoms over time 
and monitor effectiveness of treatments (90). A detailed opioid history should be taken on all patients 
prior to initiation of opioid medications to assess for tolerance, efficacy and to guide initial dosing.
6.3.1  Dyspnea
Dyspnea is a common symptom and can be severe at the end of life in COVID-19. Re-positioning can 
be used including sitting upright to increase peak ventilation and reduce airway obstruction (91). 
Therapy that is considered higher risk of transmitting COVID-19 to health care workers and family 
include: a fan, oxygen flow greater than 6L/min, continuous positive airway pressure (CPAP), bilevel 
positive airway pressure (BiPAP) and nebulized medication treatments (92). Appropriate PPE must be 
utilized as per hospital policy if these interventions are used. If a patient is intubated and withdrawal 
of therapy is appropriate it is best to do this as per hospital protocol to reduce the risk of COVID-19 
transmission to others.
Pharmacologic agents, including opioids, are the mainstay treatment for the relief of severe dyspnea. 
For patients on OAT, collaboration between the addiction medicine team or OAT prescriber will be key 
to determining whether OAT can be modified to be dosed more frequently, additional agents should 
be added, or medications should be changed to a different opioid entirely. If dyspnea is present the 
majority of the time, opioids should be dosed around-the-clock and consideration should be given to 
providing as needed opioids for breakthrough dyspnea. When initiating or titrating opioids, consider 
prescribing medications for the management of common side effects such as anti-emetic and laxative 
medications.
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Dyspnea is often associated with increased anxiety and many patients benefit from specific anxiety 
management. If there is a history of seizure (e.g. alcohol withdrawal seizures) or the patient is at 
increased risk of extrapyramidal side-effects (e.g. Parkinson’s), benzodiazepines are recommended. 
However, given their risk of delirium, neuroleptics at low dose are often preferred. Commonly 
prescribed neuroleptics are haloperidol, olanzapine, and methotrimeprazine as all can be administered 
orally or parenterally including subcutaneously. As with opioids, with severe symptoms, dose titration 
should occur and the patient will likely need around the clock dosing or an infusion if symptoms are 
refractory. Additionally, relief of severe dyspnea may require use of medications that are sedating 
(e.g. methotrimeprazine) and/or have quick onset of action (e.g. midazolam).
Medications used to control symptoms, such as opioids and benzodiazepines, may be a trigger for 
individuals who use substances (93). The use of these medications should be reviewed with the 
patient if they are well enough to engage in a conversation. However, if indicated for symptom 
management, these medications should never be withheld in those at the end of life because of past 
or current substance use.
6.3.2  Cough
Significant overlap exists between the treatments for cough and dyspnea. Non-pharmacological 
treatment such as repositioning can be initiated. For distressing symptoms of cough, opioids can be 
initiated if the patient is not already on opioids or OAT.
6.3.3  Upper respiratory secretions
At end of life, noisy upper airway secretions may develop due to an inability to clear secretions. 
Re-positioning can improve symptoms. Parenteral fluids should be reassessed as they may be 
contributing to the amount of secretions. In the last days or hours, fluids do not change prognosis and 
do not need to be routinely offered if there are no symptoms of opioid neurotoxicity (e.g. myoclonus, 
hallucinations). Glycopyrrolate can be useful in managing symptoms; if ineffective, scopolamine 
can be used instead, however it can be more sedating. In addition to thickening secretions, these 
medications also have anticholinergic side effects which can be bothersome if initiated too early. 
Deep tracheal suctioning and open airway suctioning should be avoided in patients with COVID-19 
due to the risk of aerosolization of the virus (92).
6.3.4  Fever
If the patient has discomfort from fever, acetaminophen can be given orally or rectally. If goals of care 
are comfort and treatment for fever is symptom focused, then acetaminophen can be considered in 
those with elevated liver function testing without further monitoring.
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6.3.5  Pain
Pain can be multifaceted in nature and is termed ‘total pain’ in the setting of significant psychological, 
emotional, and spiritual suffering along with physical pain. Titration and changes in opioids should 
be managed in a collaborative approach for patients on OAT. Similar to management of dyspnea, if 
pain is present the majority of the time, opioids should be dosed around the clock and consideration 
should be given to providing as needed opioids for breakthrough pain. When initiating or titrating 
opioids, consider prescribing medications for the common side effects such as anti-emetic and 
laxative medications.
6.3.6  Delirium
Delirium is common at the end of life and often multifactorial in nature. Delirium or altered mental 
status can interfere with a thorough symptom and risk factor assessment for COVID-19. Investigations 
and treatment of reversible causes should be aligned with goals of care. Commonly advised 
non-pharmacologic options, such as the presence of family or friends, are more challenging in the 
setting of COVID-19. If the delirium is episodic and mild in intensity, then the neuroleptics should 
be initially prescribed on an as needed basis to manage the agitation, distress, and confusion. For 
delirium that is irreversible and due to underlying disease progression, neuroleptics may be needed 
around the clock to manage ongoing agitation and anxiety. If haloperidol around the clock is no longer 
effective another agent can be trialed such as loxapine or methotrimeprazine. Methotrimeprazine 
is often more effective for hyperactive delirium leading to increased agitation; however, is more 
sedating. Irreversible delirium, progressing rapidly over days or even hours, is a poor prognostic 
indicator, so this should be conveyed to friends and family. Education should be provided to family 
and/or friends including the challenges of assessing other symptoms in the setting of delirium. It is 
not uncommon for family supports to misconstrue periods of somnolence and hypoactivity as being 
depression or overuse of medications, and periods of agitation or hyperactivity as pain, so education 
and reassurance is important. When delirium occurs at the end of life, it is a time to advocate that 
visits by family, friends and spiritual leaders, be facilitated, if at all possible.
6.4  OTHER CONSIDERATIONS
6.4.1  Palliative Care Consultation
If symptoms are persisting or additional advice around conversations and direction of care are 
needed, consider consulting your local palliative care team.
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6.4.2  Palliative care in other settings
Palliative care should be available in all settings including home, hospital, hospice, long term care, 
and shelters. The Canadian government has released information on how to care for a person with 
COVID-19 at home which should be applied to any location that a patient identifies as home (94). 
Requests for Medical Assistance in Dying (MAID) do not change the course of palliative care and 
MAID referrals are region specific.
6.4.3  Psychological and grief support
Those affected by COVID-19 and their supports can have a psychological burden that is complicated 
by factors such as isolation and financial strain (95). Family and friends that experience death of 
a loved one will experience grief, a universal human process. Referral for grief services should be 
considered for friends and family of those affected. Family units should not be assumed, and contact 
information should be gathered by the attending health care team.
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7.0  Addressing other health needs 
In addition to identifying and initiating treatment and referral for substance use disorders, a period 
of hospitalization can also be an opportunity to address other unmet health and social needs. Four 
areas of particular relevance during COVID-19 include addressing mental health concerns, ensuring 
the social determinants of health are assessed, preventing future infections via immunization, and 
identifying any other untreated infections. Others areas of intervention that could be considered if 
feasible and appropriate include addressing sexual health and contraception needs. 
7.1  MENTAL HEALTH CONCERNS
People with mental health disorders may be more susceptible to COVID-19, more substantially 
influenced by the emotional responses brought on by the COVID-19 pandemic, and/or unable 
to access their usual mental health supports (96). Patients should be screened for mental health 
concerns and referred to treatment or local supports as clinically indicated.
7.2  SOCIAL DETERMINANTS OF HEALTH
Effective medical treatment also involves understanding and appreciating a patient’s social 
determinants of health. All patients should be asked about the availability and safety of housing, 
screened for poverty or inadequate legal income, and assessed for active medication coverage.  Early 
involvement of social workers can be critical in addressing unmet social needs and ensuring that 
patients can comply with any isolation requirements after hospital discharge (97).
7.3  IMMUNIZATIONS
Some patients who use substances are at risk of developing vaccine preventable infections. In 
particular, patients who are immunocompromised, have liver failure or cirrhosis, or live in shelters are 
eligible for extended adult vaccination regimens. Where possible, consider offering immunizations 
during a period of hospitalization as a highly cost effective way to reduce future morbidity and 
mortality (98).
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7.4  SCREENING FOR SEXUALLY TRANSMITTED AND 
BLOOD BORNE INFECTIONS
Some patients who use substances may also be at risk of sexually transmitted and blood borne 
infections. If a patient consents, screening should be performed in hospital so that treatment and any 
appropriate referrals can be initiated (99).
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8.0  Transfer of care to community 
providers at discharge
8.1  GENERAL CONSIDERATIONS
A discharge checklist can be found in Appendix 2. At the time of discharge, any active infection 
prevention and control issues need to be clarified. If appropriate, providing patients with a discharge 
letter stating that the individual has completed the legal/medical requirements of isolation and is safe 
to return to the community can reduce the risk of unfounded discrimination or refused re-entry into 
congregate living environments. Additionally, if clinically indicated, ensure the patient still has the 
take home naloxone kit provided earlier in the admission as well as up to a two week supply of sterile 
drug use equipment.
8.2  DISCHARGE TO HOME
If a patient is discharging home, ensure this remains a safe disposition plan. If the patient requires 
ongoing isolation, ensure that this will be possible within their home, that there is support 
for basic necessities (e.g. someone able to deliver them food, medication, cleaning supplies), 
and that the patient understands how to safely self-isolate. Patients on self-isolation will also 
need medications delivered and virtual follow-up appointments arranged until the requirement 
for self-isolation ends. If the patient is required to leave their home, then they must wear a 
mask. Confirmation of active medication coverage and income support is important to ensure a 
seamless discharge back to the community. 
Even if the patient is not required to self-isolate, community providers may be following up with 
their patients via telehealth or other virtual care platforms. When able, coordinate virtual and/
or phone follow ups to support patients to adhere to physical distancing recommendations in 
the community. Confirm whether the patient has access to a telephone or technology and, with 
consent, provide this contact information to the ongoing community provider and pharmacist.
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8.3  TRANSFER TO AN INPATIENT ADDICTION 
TREATMENT PROGRAM
Even during the COVID-19 pandemic, some inpatient addiction treatment programs may still be 
accepting patients. When possible, and if desired by the patient, transfer from an acute care setting 
directly to a specialized addiction treatment program should be facilitated whenever possible. Patients 
admitted to an acute care setting who have stopped using substances and had their withdrawal 
managed will likely meet program requirements (if any) of a period of abstinence from substance use 
prior to admission. Direct transfer from acute care minimizes the risk of relapse which would then 
require another period of detoxification prior to program admission.
Prior to transfer it will be important to confirm program admission requirements (including COVID-19 
specific changes) and whether the program can accommodate isolation requirements (if still needed). 
A plan for any ongoing prescribing should be coordinated with the program’s medical team or the 
patient’s primary care provider. In addition, some programs require that prescriptions be sent to a 
specific pharmacy for the duration of the treatment program.
8.4  TRANSFER TO AN EMERGENCY SHELTER
In response to the pandemic, many jurisdictions have adapted their existing shelters to comply 
with physical distancing requirements or moved to new settings (e.g. hotels, convention centres) to 
establish medical isolation shelters. As the pandemic evolves, many shelter settings are fluid and 
are adapting to the needs of the clients accessing their site(s). It is important to be aware of what 
services are offered on site and, for those services that are not, how patients can be supported to 
access the services they need. Prior to discharge, the acute care team should confirm with the site 
Infection Prevention and Control team (or Public Health, depending on hospital procedure) whether 
the isolation period has ended, and if not, that appropriate isolation facilities are available at the 
discharging facility.
8.4.1  Adapted shelter (a shelter setting where patients are 
not required to self-isolate)
Prior to discharging to shelter, the acute care team should confirm that the patient is agreeable to 
stay at the shelter and whether there is current availability. 
In an adapted shelter setting, the patient may still be able to present to their pharmacy for witnessed 
ingestion and/or medication pick up. Carries and/or decreased frequency of dispensing may be 
appropriate to promote physical distancing based on a shared decision making process between 
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patient and provider. Decisions regarding carries should be made in collaboration with the patient’s 
community prescriber. If carries are not appropriate and/or the patient is unable to present to the 
pharmacy, other options for ongoing medication access may include having the patient’s community 
pharmacy deliver daily to the shelter or deliver several days of medications if safe to do so and there 
is access to a secure storage space. Confirmation of access to secure storage space at the shelter 
should be confirmed prior to discharge. 
8.4.2  Medical Isolation Shelter (shelter setting where 
patients are required to self-isolate)
Each acute care setting should establish a seamless care pathway to the medical isolation shelter (if 
available). It is necessary to have clear communication and an understanding of the requirements, 
expectations, and services available at the shelter to ensure patients are supported in their transition 
between settings. Acute care providers should be well informed of both admission and exclusion 
criteria for the medical isolation shelter. 
Prior to coordinating transfer to a medical isolation shelter, it is essential that the patient be informed 
of this plan. Patients should be supported to understand why discharge to a medical isolation shelter 
is required and what supports are available on site.
Acute care providers should be aware of what, if any, medical supports are available on site 
including access to primary care, access to OAT providers, and/or access to pharmacy services. If 
there are medical supports on site, this may result in a change from the patient’s original community 
connections. As part of the seamless care pathway, it is important to establish who is responsible for 
notifying the patient’s existing community provider and community pharmacy of the transfer of care. 
Acute care settings should consider the most appropriate and safest mode of transport to the medical 
isolation shelter. Transport must abide by local recommendations for infection prevention and control 
for both the patient and staff. This may vary by jurisdiction and availability of resources. In the event 
a patient does not successfully arrive at the medical isolation shelter, there should be a clear plan for 
next actions including connecting with Public Health to determine appropriate measures to locate 
the patient (which may be dependent on whether the patient was known to be COVID-19 positive or 
under investigation) and, as appropriate, re-activating the patient’s previous community connections 
and prescriptions for ongoing care.
On discharge from the shelter, the shelter medical team should reconnect patients to their existing 
community connections or, as required, refer them to new providers for ongoing care.
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8.5  DISCHARGE PRESCRIBING
The acute care team must collaborate with the patient’s community providers to coordinate seamless 
care and ongoing prescribing. Furthermore, early collaboration between the acute care team with a 
hospital or community pharmacist is important to proactively identify any barriers to seamless care 
planning including drug shortages and ability to continue therapy. Prior to discharge, it is essential 
to confirm that medication coverage is active. For those without coverage, collaborate with a social 
worker to ensure coverage is in place before discharge. 
Community providers may be following up with their patients via telehealth or other virtual care 
platforms. Consider providing a lengthier discharge prescription than usual to accommodate for 
the time it may take for the patient to reconnect with their prescriber in this new climate. For all 
prescriptions, ensure it does not lapse on a Friday, weekend, or statutory holiday. For OAT bridge 
prescriptions, include documentation of the milligram dose and date last received in hospital, 
dispensing frequency (i.e. daily versus carries), who will be taking over prescribing as well as 
follow up appointment details, instruction on when doses are to be held, instruction for missed 
dose management, who to notify of missed doses, and whether medications can be released to 
an authorized individual if the patient is unavailable to receive their delivery directly. If carries are 
authorized, clearly document the quantity of carries approved and confirm that the patient is able 
to securely store the carries (at minimum, a bag that can close with two zippers along with a lock to 
secure the two zippers together). Patients may not be required to keep or return their empty carry 
containers due to the risk of COVID-19 transmission however alternate arrangements, as required, 
can be explored between the patient, pharmacist, and OAT prescriber. 
As part of the COVID-19 pandemic response and in an effort to support seamless care, Health Canada 
has issued certain exemptions for prescriptions of controlled substances under the Controlled Drugs 
and Substances Act (CDSA) and its Regulations. These exemptions permit the extension and transfer 
of prescriptions of controlled substances by pharmacists, the delivery of controlled substances by 
pharmacy employees to patient’s homes or other locations they are staying, as well as permitting 
prescribers to issue verbal orders to extend or refill prescriptions for controlled substances. Please 
refer to the Health Canada Subsection 56(1) Class Exemption for Patients, Practitioners, and 
Pharmacists Prescribing and Providing Controlled Substances in Canada during the Coronavirus 
Pandemic for further details regarding the exemptions and their application to specific provincial/
territorial scopes of practice.
Discharge planning to a medical isolation shelter should be tailored based on the services offered at 
the shelter. If there are medical supports available, a bridge prescription for OAT or other medications 
may not be required as long as clear and direct communication occurs regarding the need for isolation 
shelter medical staff to manage ongoing prescribing. If pharmacy services are available at the isolation 
shelter, it is essential that the discharge prescription be sent to the isolation shelter pharmacy, if 
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different than their usual pharmacy, for continuity of care. Patients may be required to present with 
a 24-hour supply of their discharge medications. Not all medications may be appropriate to provide 
as a bridge supply. For those medications, it is best to administer the medication in the acute care 
setting prior to discharge. This can be communicated to isolation shelter medical staff in the discharge 
process and/or by faxing a copy of the medication administration record from the hospital.
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Appendix 1  Conflict of Interest 
Policy
Conflicts of interest were assessed using the Guidelines International Network’s Principles for 
Disclosure of Interests and Management of Conflicts (i). For this Guidance document, authorship 
committee members and external reviewers were required to disclose all sources and amounts of 
direct and indirect remuneration received in the past five years from industry, for-profit enterprises, 
and other entities (e.g., direct financial conflicts) that could introduce real, potential, or perceived 
risk of bias. In addition, authorship committee members and external reviewers were asked to 
disclose possible indirect conflicts of interest, such as academic advancement, clinical revenue, 
and professional or public standing that could potentially influence interpretation of evidence and 
formulation of recommendations.
Before the draft guidance document was circulated for review, two CRISM staff members 
independently reviewed the disclosure forms to screen potential authorship committee members and 
external reviewers who should be precluded from participation due to ongoing or current financial 
relationships (e.g., employment, paid consultancy or advisory board membership, stock ownership, 
intellectual property) with industry or commercial entities that could theoretically benefit from 
the guidance document recommendations. Consistent with the Institute of Medicine Standards for 
Developing Trustworthy Clinical Practice Guidelines, any individual with a current, ongoing relationship 
with industry, who had received any remuneration or non-monetary support from industry within 
the past 12 months, or with a history of significant remuneration or non-monetary support from 
industry (defined for our purposes as cumulative receipt of more than $10,000 or equivalent value 
within the past five years), was excluded from participation on the guidance document prior to the 
review process. No authors nor contributors were excluded during initial screening as none met these 
criteria for exclusion.
Summary of disclosures
Of 30 authorship committee members and external reviewers, 14 acknowledged potential direct 
conflicts of interest. Of these, 10 acknowledged employment or consulting with organizations 
including academic institutions, hospitals/health authorities, professional or regulatory associations, 
HIV/AIDS foundations, community outreach agencies or federal funding agencies. Only one (an 
external reviewer) disclosed receiving research funding prior to guidance document involvement 
i.   Schünemann HJ, Al-Ansary LA, Forland F, et al. Guidelines international network: principles for disclosure of interests and management of 
conflicts in guidelines. Ann Intern Med. 2015;163(7):548-553.
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from a commercial entity (Gilead) that could theoretically benefit from guidance document 
recommendations. There was one authorship committee member with a commercial interest in the 
form of partial ownership of a medical clinic that provides treatment to PWUD. On review, potential 
conflicts of interest were not deemed to be of sufficient weight or relevance to warrant exclusion 
from the guidance committee.
Most (23, 77%) authorship committee members and external reviewers disclosed potential indirect 
sources of bias (e.g., specialization in addiction medicine, advisory board and committee membership, 
involvement with acute care programs, provincial substance use treatment programs, previous 
guideline development, research interests). Of these, 6 acknowledged that they have publicly stated 
support for acute care treatment of PWUD. In order to mitigate the risk of bias while maximizing 
the contributions of members in their respective areas of expertise, authorship committee members 
and external reviewers were reminded to consider any influential factors or sources of bias during 
the review process. Authors and reviewers with indirect potential sources of conflict contributed to 
review of sections related to their areas of expertise as well as the overarching guideline content to 
ensure that a broad range of clinical and academic specializations was adequately represented.
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Appendix 2: Discharge Checklist
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Appendix 3: Online Substance Use 
Resource Listing
Below is a list of online resources on substance use. Please note that this is not an exhaustive list of 
resources.
Subsection 3.1  Clinical Support Resources for Patients and 
Healthcare Providers
Anxiety Canada’s free MindShift™ CBT app 
This app focuses on assisting in the management of anxiety using scientifically proven strategies (free 
for iOS and Android devices) 
British Columbia Centre on Substance Use: COVID‑19
Canadian Addiction Counsellors Certification Federation
Virtual addiction counselling
CATIE – Canada’s source for HIV and hepatitis C information
College of Physicians and Surgeons of Newfoundland and Labrador - Opioid Agonist Treatment 
(OAT) Guidance during COVID-19
Community Addictions Peers Support Association (CAPSA) and Breaking Free Online
In response to COVID-19 and the increased risks for those with substance use disorders, the 
Community Addictions Peers Support Association (CAPSA) has partnered with Breaking Free Online 
to provide free access to Canadians (service code CAPSA2020)
Draft Emergency Carry Agreement 
Nova Scotia Department of Health and Wellness: Points to Guide Clinical Decision for OAT 
Prescribers
Nova Scotia Health Authority (NSHA) Standard Operating Procedures for Opioid Use Disorder 
Treatment (OUDT) Programs
Documents included: Overview and Infection Control Practices SOP, New Admissions and Transfers 
SOP, Ongoing Client Being Prescribed Methadone SOP, and Clients in Self-Isolation or Quarantine SOP.
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Providence Health Care Nursing Practice Standard Dispensing Injectable Opioid Agonist Therapy to 
Client With or at Risk of COVID‑19
SMART Recovery Program 
This website includes message boards, chat rooms, online meetings, and an online library of recovery 
resources
Take Home Naloxone
Free online naloxone training 
Toward the Heart
Free online naloxone training
Subsection 3.2 Harm Reduction Resources
Canadian Association of People Who Use Drugs (CAPUD) 
Canadian Drug Policy Coalition: COVID‑19 Harm Reduction Resources
International Network of People Who Used Drugs: COVID‑19 Crisis: Harm Reduction Resources for 
People who Use Drugs
Subsection 3.3 Mental Health and Substance Use Resources 
Centre for Addiction and Mental Health (CAMH): Mental Health and the COVID‑19 Pandemic
Narcotics Anonymous
Taking Care of Your Mental Health (COVID-19)
Wellness Together Canada: Mental Health and Substance Use Support
Subsection 3.4 Indigenous Communities
Assembly of First Nations: COVID‑19
First Nations Health Managers Association: COVID‑19 Resources and Announcement
Up-to-date information on COVID-19
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First Peoples Wellness Circle: COVID‑19 Resources page
Provides printable Information Sheets for Mental Wellness for Community; Parents and Children; 
Elders and Seniors; and Health Professionals
Thunderbird Partnership Foundation: Harm Reduction during COVID‑19
Subsection 3.5 Support Resources for Healthcare Providers
Canadian Foundation for Healthcare Improvement (CFHI)
Supports partners to accelerate the identification, spread and scale of proven healthcare innovations. 
Webinar Series: Patient Partnership in a Time of COVID-19
Government of Canada Coronavirus disease (COVID-19) resources for health professionals.
Health Canada Subsection 56(1) Class Exemption for Patients, Practitioners and Pharmacists 
Prescribing and Providing Controlled Substances in Canada during the Coronavirus Pandemic 
In response to the evolving health risk due to COVID-19, to maintain Canadians’ access to controlled 
substances for medical treatments (e.g., treatment of substance use disorders and chronic pain), 
while they adhere to social distancing guidance from public health officials or if they need to self-
isolate, Health Canada has issued exemptions for prescriptions of controlled substances under the 
Controlled Drugs and Substances Act (CDSA) and its Regulations.
Mental Health First Aid Canada
Resource hub which provides credible information and resources for mental health for the Healthcare 
professionals “Resources for Healthcare Sector” 
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Appendix 4: Health Canada Tool Kit
Health Canada has compiled a number of resources in an effort to provide clarity regarding the rules 
that apply for substance use disorder treatment or providing a pharmaceutical grade alternative to 
the toxic street supply in Canada, in the context of COVID-19. This includes:
• A regulatory pathways graphic;
• Frequently asked questions and answers related to the legislative and regulatory requirements 
for substance use disorder treatment/safer supply;
• A list of all relevant exemptions that have been issued under the Controlled Drugs and 
Substances Act;
• Formulary coverage under drug plans of medications used in substance use disorder treatment 
and as pharmaceutical grade alternatives to the illegal supply; and,
• Resources related to substance use disorder treatment and providing safer supply, both in 
general and during the COVID-19 pandemic.
https://www.dropbox.com/sh/x622qndzvmydsvm/AABi888G_Ase6T0-N1Pd3uboa?dl=0
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